|
|
Vaccine Detail
|
pTVG-HP Plasmid DNA Vaccine |
| Vaccine Information |
- Vaccine Name: pTVG-HP Plasmid DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007158
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Pap antigen
gene engineering:
- Preparation: This is a plasmid DNA-based (pTVG-HP) vaccine encoding PAP (Johnson et al., 2007).
- Description: This is for Prostate Cancer (NCT02499835). A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer. (NCIT_C82407).
|
| Host Response |
|
|
| References |
Johnson et al., 2007: Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer immunology, immunotherapy : CII. 2007; 56(6); 885-895. [PubMed: 17102977].
NCIT_C82407: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82407]
NCT02499835: [https://clinicaltrials.gov/show/NCT02499835]
|
|
